Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13624)	1/23/1998 12:31:00 AM
From: Proton	Read Replies (2) \| Respond to of 32384

Re: "... the info wasn't all that good" May be an Understatement Press releases can bury the news. Here's how I read it (fair use excerpt from tonight's TheStreet.com): Pfizer (PFE:NYSE) said interim clinical trial results for its droloxifene drug for advanced breast cancer showed no benefit beyond the current therapy, so it is switching the development program's focus to preventing osteoporosis. Does this mean "bye-bye" to the 4Q97 NDA for droloxifene? Does this mean "see ya" for the milestone payment? Does this toss a big bucket of liquid nitrogen on Portlas' "cyclical upswing" thesis? I don't know the answers, but I dislike the questions. :-O We may see exactly how closely watched LGND is tomorrow. Pý